CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a specialized
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin peptide
receptor system, announced the presentation of the protective
effects of melanocortin 1 receptor agonists PL8331 and PL9654 in
mouse models of retinopathy, at the 2021 Annual Meeting of the
American Society of Retina Specialists (ASRS), being held virtually
October 8-12, 2021.
The presentation highlights the positive pre-clinical data in
mouse models of retinopathy, and the possible utility of
melanocortin receptor agonists in the treatment of diabetic
retinopathy and choroidal neovascularization.
"The research and development team at Palatin continues to
produce positive data in inflammatory disease models, including
front of the eye, the gastrointestinal system, and now back of the
eye," said Carl Spana, Ph.D.,
President and Chief Executive Officer of Palatin. "Our
preclinical and clinical research continues to build support for
the melanocortin system as a target for treating a wide range of
inflammatory diseases. The preclinical retina inflammation data is
exciting and provides support for moving compounds in our robust
melanocortin agonist platform towards human clinical
studies."
Presentation
details:
|
Date:
|
October 9,
2021
|
Time:
|
5:35 pm to 6:35 pm
Central Time
|
Format:
|
Poster
Presentation
|
Presenter:
|
John Dodd, Ph.D.,
Palatin Preclinical Development
|
Title:
|
"Protective Effects
of Two Melanocortin Agonists Delivered by Intravitreal
Injection in Mouse Models of Retinopathy"
|
About Melanocortin Receptor Agonists and
Inflammation
The melanocortin receptor ("MCr") system has
effects on inflammation, immune system responses, metabolism, food
intake, and sexual function. There are five melanocortin receptors,
MC1r through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have medically significant pharmacological effects.
Many tissues and immune cells located in the eye (and other
places, like the gut and kidney) express melanocortin receptors,
empowering our opportunity to directly activate natural pathways to
resolve disease inflammation.
About Palatin
Palatin is a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin and natriuretic peptide
receptor systems, with targeted, receptor-specific product
candidates for the treatment of diseases with significant unmet
medical need and commercial potential. Palatin's strategy is to
develop products and then form marketing collaborations with
industry leaders to maximize their commercial potential. For
additional information regarding Palatin, please visit Palatin's
website at www.palatin.com.
Forward-looking Statements
Statements in this press
release that are not historical facts, including statements about
future expectations of Palatin, such as statements about clinical
trial plans and potential results for clinical or pre-clinical
programs, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Palatin intends
that such forward-looking statements be subject to the safe harbors
created thereby. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that could cause
Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating for events that
occur after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-announces-presentation-of-positive-protective-effects-of-pl8331-and-pl9654-on-retinal-inflammation-at-the-2021-american-society-of-retina-specialists-asrs-annual-meeting-301385088.html
SOURCE Palatin Technologies, Inc.